BillionToOne, Inc. (BLLN) vs CRISPR Therapeutics AG (CRSP)

A side-by-side comparison of BillionToOne, Inc. and CRISPR Therapeutics AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
BillionToOne, Inc. logo
BLLN
BillionToOne, Inc.
$4.64B
$100.88HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
CRISPR Therapeutics AG logo
CRSP
CRISPR Therapeutics AG
$5.28B
$54.75HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT

Total return — BLLN vs CRSP

growth of $100 · dividends reinvested · last 1y
BLLN +0.1% (+0.1%/yr)CRSP +0.6% (+0.6%/yr)CRSP compounded faster over this window
6080100120140Start $1002026$100$101
BLLN CRSP

BLLN vs CRSP: by the numbers

  • •CRSP is the larger company ($5.28B vs $4.64B market cap).
  • •BLLN is profitable (8.43% net margin) while CRSP runs a net loss (-3368.72%).

Metrics side by side

Valuation

MetricBLLNCRSP
P/E ratio162.68N/A
Forward P/E127.01N/A
P/S ratio11.68394.31
P/B ratio8.643.02
EV / EBITDA76.17N/A
FCF yield0.71%N/A

Profitability

MetricBLLNCRSP
Gross margin71.27%-6537.01%
Operating margin10.90%-16191.40%
Net margin8.43%-3368.72%
ROE6.24%-25.83%
ROIC6.39%-21.12%

Growth (annualized)

MetricBLLNCRSP
Revenue CAGR (5Y)N/A37.32%
Total return CAGR (5Y)N/A-10.97%

Frequently asked

Is BLLN or CRSP more profitable?
BLLN runs the higher net margin — BLLN at 8.43% versus CRSP at -3368.72%.

Go deeper

Full BLLN analysisFull CRSP analysisInteractive comparison tool

Dig into the metrics

BillionToOne P/E ratioBillionToOne ROECRISPR Therapeutics AG ROEBillionToOne operating marginCRISPR Therapeutics AG operating marginBillionToOne revenue growthCRISPR Therapeutics AG revenue growthBillionToOne free cash flowCRISPR Therapeutics AG free cash flow

BillionToOne & CRISPR Therapeutics AG appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.